A Cross Sectional Study on the Cost Effectiveness of Antibiotics Used In Intensive Care Unit Patients Attending Tertiary Care Hospital
Keywords:
Intensive care units (ICU), Cost-effectiveness analysis (CEA), AntibioticsAbstract
Background: In intensive care units (ICU), antibiotics are routinely prescribed to treat severe infections. cost-effectiveness analysis (CEA) is a technique used to assess the outcomes and costs of different strategies aimed at improving health, and has been utilized in various scientific disciplines.
Aim And Objectives: To identify the most commonly prescribed antibiotics in ICU and To estimate the cost of antibiotics used in ICU patients.
Materials And Methods: After IEC approval, This Cross sectional observational study was conducted in Medical Record Department of MAPIMS Hospital for 6 months. Sample size was found to be 385. The Indian Drug Review and the Current Index of Medical Specialties provide the brand cost of the medication
Results: In this study, antibiotics were prescribed in 231 out of 312 case records accounting 74%. The cost per dose in ICU patients ranges from Rs 7.55 to Rs 800 (per dose). The most commonly prescribed injectable antibiotics were Ceftriaxonefollowed by Metronidazole, Piperacillin/Tazobactam, while, oral antibiotic was Tab. Doxycycline, Ciprofloxacin, Augmentin, Azithromycin, Taxim, ofloxacin and Linezolid
Conclusion: The most cost-effective antibiotics were Tab. Doxycycline and Inj. Ceftriaxone.. To alleviate the financial burden on healthcare facilities, it is essential to conduct regular prescription audits and modify antibiotic policies.
Downloads
Metrics
References
Asumanİnan, OzgurDağlı, SenihaŞenbayrakAkcay, Derya Ozturk Engin, EminKaragul, SeyfiCelikOzyurek. Antibiotic use and cost in a teaching hospital in İstanbul. J Microbiol Infect Dis. (2011), [cited July 05, 2024]; 1(3): 128-133
Jayaram R, Ramakrishnan N. Cost of intensive care in India. Indian J Crit Care Med. 2008 Apr;12(2):55-61.
Mittal, N.; Tayal, A.; Kumar, S.; Dhawan, R.; Goel, N.; Mittal, R. Longitudinal Trends in In-Patient Antibiotic Consumption According to the WHO Access, Watch, Reserve (AWaRe) Antibiotic Groups and Cost: An Analysis of Data at a National Antimicrobial Consumption Network (NAC-NET) Site in North India over 7 Years (2017–2023). Antibiotics 2024, 13, 673
Pharmaceuticals. India brand equity foundation Web site:https://www.ibef.org/download/Pharmaceutical-March-2017.pdf. Updated March, 2017. Accessed on Feb 17, 2025.
Gautam, Ashish. (2021). Antibiotic utilization, sensitivity, and cost in the medical intensive care unit of a tertiary care teaching hospital in Nepal. SAGE Open Medicine. 10.1177/2F20503121211043710
Current Index of Medical Specialities; 2005. Available from:https://www.flipkart.com/cims-current-index-medical-specialities-oct-jan-2025/p/itm9a3510e68ea93.
Indian Drug Review; 2023. Available from: https://www.jainbookagency.com/newdetails.aspx?id=6690.
Atal S, Mathur A, Balakrishnan S. Cost of Treating Bacterial Infections in India: A Cost Minimization Analysis to Assess Price Variations. Biomed Pharmacol J 2020;13(2).
Acharya P, Karabasanawar SS, Sattigeri AR, Pai VP, Totar LB, Nyamagoud SB. Cost-effectiveness and economic analysis of antibiotics: a comprehensive study utilizing ICER and ACER metrics. MGMJ Med Sci 2024;11:714-21
Wong G, Briscoe S, Adnan S, McWhinney B, Ungerer J, Lipman J, Roberts JA. 2013. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother 57:6165–6170. doi: 10.1128/AAC.00951-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
Schleibinger M, Steinbach CL, Töpper C, Kratzer A, Liebchen U, Kees F, Salzberger B, Kees MG. 2015. Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. Br J Clin Pharmacol 80:525–533. doi: 10.1111/bcp.12636. [DOI] [PMC free article] [PubMed] [Google Scholar]
Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. 2001. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J AntimicrobChemother 47:421–429. doi: 10.1093/jac/47.4.421. [DOI] [PubMed] [Google Scholar]
Selmi V, Loriga B, Vitali L, Carlucci M, Di Filippo A, Carta G, Sgambati E, Tofani L, De Gaudio AR, Novelli A, Adembri C. 2016. Changes in ceftriaxone pharmacokinetics/pharmacodynamics during the early phase of sepsis: a prospective, experimental study in the rat. J Transl Med 14:316. doi: 10.1186/s12967-016-1072-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
Steigbgel, NH, reed LW, Finland M. Absorption and excretion of five tetracycline analogous in normal young men. American Journal of medical sciences, 1968, 255:296.
Edwards SJ, Campbell HE, Plumb JM. Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care. Eur J Health Econ 2006 Mar; 7(1): 72–8
Kulikov A, Krysanov I, Lomakin A. Antibiotic therapy of nosocomial infection in the intensive care unit: a cost-effectiveness analysis [abstract no. PIN4 plus poster]. Value Health 2006; 9: A299
Sonja Löfmark, CharlottaEdlund, Carl Erik Nord, Metronidazole Is Still the Drug of Choice for Treatment of Anaerobic Infections, Clinical Infectious Diseases, Volume 50, Issue Supplement_1, February 2010, Pages S16–S23, https://doi.org/10.1086/647939
Hitt CM, Klepser ME, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy. 1997 Jul-Aug;17(4):810-4. PMID: 9250562.
Gonzalez LS 3rd, Spencer JP. Aminoglycosides: a practical review. Am Fam Physician. 1998 Nov 15;58(8):1811-20. PMID: 9835856.
National Treatment Guidelines for Antimicrobial Use in Infectious Diseases 2016. National Centre for Disease Control Web site. http://pbhealth.gov.in/amr_guideline7001495889.pdf. Accessed Feb 4, 2025.
Treatment Guidelines for Antimicrobial Use in Common Syndromes 2019. 2nd edition. ICMR, New Delhi. https://www.icmr.nic.in/guidelines/treatment%20guidelines%20for%20antimicrobial.pdf. Accessed Feb 15. 2025.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
